Summit Therapeutics said that it had highlighted the potential of its pre-clinical new class antibiotic to treat all gonorrhoea, including multi-drug resistant strains, at the STI & HIV World Congress in Vancouver, Canada.
'The problem of gonorrhoea resistance is very concerning, and if nothing is done, physicians could see more and more cases of untreatable disease,' said R&D president David Roblin
'As shown by the pre-clinical data presented, our gonorrhoea-targeted new class antibiotic, SMT-571, has the potential to overcome known resistance mechanisms across global isolates, including multi- and extensively-drug resistant strains.'
'Further, there is a clear need for new gonorrhoea treatment options that would allow ceftriaxone to be reserved for the multitude of other serious infections that rely on its potency.'
At 1:08pm: (LON:SUMM) Summit Therapeutics PLC share price was +0.25p at 24.25p